call and joining to Melissa, everyone us you on and today's Thank you very much, webcast. thank
to that take any I'd a assess ongoing started, we potential pandemic COVID-XX like acknowledge get we actively to impacts business. monitoring Before our the are to moment to
clinical and well medical programs. as involved in the our the is ongoing one safety course, our professionals health number Our and patients priority of of employees, as
any our At this ongoing interruption guidance. on impact programs, or time, not we nor to anticipate any delays financial we do our expect clinical do
monitor provide will we'll and to as continue We the necessary. situation, evolving updates
now realize with Let a current to than in provides to high-level which a strive corporate Slide summary live our future, as ever priorities, which longer and we people us of cancer before. better turn X,
As we tremendously be turning company. year and our XXXX anticipated, had is out a to for exciting transformative
last this year, response March we presented our Since by approximately menin-MLLX inhibition that the leukemias acute under patients our induce to we MLL-r inhibitor SNDX-XXXX, successful call balance of clinical announced the terms. million addition attractive first with the of have can and Menin of in evidence interaction sheet in our $XXX
breast overall this potential survival a of metastatic quarter, launch near-term EXXXX us in closer cancer. and hormone the readout Moreover, receptor-positive FDA bringing to will approval filing, final occur
continue data clarify disease. we Finally, our potential of to to anti-CSF-XR the further that antibody, chronic axatilamab graft-versus-host will collect treat
versus trial So of The these patients placebo exemestane HERX-negative the and on detail. of design plus opportunities the Slide X receptor-positive the X each is trial let's Phase hormone analysis. breast of to survival exemestane, trial focus of greater entinostat cancer. XXX now the final in review randomized entinostat overall in this plus summarizes
positive protocol of discussions there XXX outcome occur events, with based will our once are analysis and this would modeling FDA. we assessment June in of be year. end terms upon the United designation States, allow approval therapy which, with breast our final cancer and before the in on our based The to conducted the special will recent believe file receptor-positive breakthrough ECOG, metastatic A regulatory us hormone for
to the months The would be launch set would positive ratio detect up X.XX. is X.XX filing, positive from statistically and regulatory significant XX% ratio hazard about within in a prepared is maximum receiving that XXXX. of hazard to us entinostat yield team power a should the which Our approximately a data trial six to trial of ECOG, submit trial the has
Based patients receiving upon combination overall assumptions, the hazard five the improvement about had ratio that a median month that design indicate if in a of would survival. X.XX, EXXXX achieved
for Slide inhibitor. X first-line in with preferred entinostat-exemestane emphasizes regimen inhibitor, a a the is single-agent to a potential given aromatase the either as after agent the be which typically combination CDKX/X or
should and Our inhibitor current a estimate prior is will have to of Thus, EXXXX highly received entering dataset patients patient trial. population. in relevant CDKX/X the that we XX% between have XX% a the post-CDKX/X in
first-line improve the entinostat physicians use. In our rapid widespread a the of outcomes setting, setting we CDKX/X patients opinion, the to In achieve with of desire adoption the expect result, associated therapies. of to positive Ibrance the and underscores would similar in as EXXXX such inhibitors, anti-estrogen
This therapy patients receive substantial estimated of in year U.S. regimen. patients the therefore, to therapy is who failing first-line and the XX,XXX with who after on receive be eligible each population to entinostat an hormone go could,
own. to our prepared entinostat the in be U.S. will we Importantly, launch on
building we internal actively team to are our We commercial into with while in well-positioned are discussions rest-of-world of potential currently partners. ensure launch potential the entering out for XXXX, commercial entinostat
entinostat provide We result Slide receptor-positive with profile, emphasizes EXXXX. essentially entinostat, OS physicians cancer breast a market preparation in that a launching qualitative X in positive and minimum have we the cancer. tested community In for could research the experts. benefit clinical hormone breast conducted potential of conservative
We physicians hormone entinostat find they be of is therapy to of patients in potential to the from both endocrine breast and for receptor-positive high there a that to feature entinostat. resensitize attractive that need ability a consistently very agents groups cancer heard novel of
minimal life patients' most and hormone survival overall saw with therapy made to their Not that quality and an the extend could endpoint impact time surprisingly, efficacy lengthen of important compelling very they on the that profile. believe agent uniformly a as survival
are patients. important EXXXX in confident to this eager remain medicine to positive and be to We the bring trial potentially potential new for a
scientific one Slide validation preclinical On and ongoing of in Let publications, Science a we me our premier one rationale to call, Cell clinical agent. and and Cancer two our X now turn in last targeted SNDX-XXXX, trial. genetically provides that our highlighted
selected publications on did present the few to will development I not month. Session the candidate, of of points. the preclinical at but website, to Horizon on last Those profile not presentation, we that AACR it is excited the details will our Drugs available involve a Therefore, the review be were SNDX-XXXX. New use our key of SNDX-XXXX quite summarize I
First, our relatively second SNDX-XXXX channel. menin-MLL CYPXAX. clinical molecule the specific is HER is a inhibitor its of note the is by off-target of activity binding And relevance, The potent of to and metabolized only weak interaction.
a conducted be On Slide X, we patients drive derive to model the plasma exposures efficacy. in summarize experiments that to think were will of detailed needed the we
had of on Slide and exposures in the a response. the in that, the on shown to We an pleased anticipated second course, as with patient we were, levels patient would exceeded indeed MLL-r complete required achieve rearrangement first X, trial that went for be and the plasma the efficacy trial
rapidly observed day was therapy. activity clinical Importantly, by of XX
dose-limiting a observed relative treatment-related activity may Of medication CYPXAX, anticipated. No what prolongation. adverse concomitant was that had account note, grade-two we exposure patient only inhibits to were and toxicities the a disproportional on the the this experience was PK QTc of for which
patients that's available Full are presentation included our AACR the website. on details in additional on
combined AUGMENT-XXX and X Accelerated the the Slide first-in-human Understanding X The trial This trial. schematically on is shown first-in-human is Phase is AUGMENT in of and clinical XX. Inhibition trial Phase updated a program or Menin trial
dose a in trial designed Phase of dose or independent dose-escalation a to two and identify refractory is maximum patients portion the X recommended Phase cohorts with X leukemia. The of tolerated relapsed SNDX-XXXX
a are Arm Arm on enrolls inhibitor CYPXAX A strong patients of CYPXAX the time on and are enrolls patients B enrollment. not who who at a inhibitor strong
period in for The evaluated first XX determining the which as days safety serves escalations. of dose dosing is
the the X, As required abnormality FDA, study. not patients a need genetic to by specific enroll to X do in Phase have
level AACR single of time three. cohorts the of completed and presentation, of evaluating one have in at evaluation are Arm the patient a A we As two and our dose
to-date. No a time toxicity. grade-two at the been design in Arm one no three-plus-three given dose-limiting had toxicities or expanded dose-limiting observed have and AACR presentation, to have B, the toxicities we grade-two of And
Phase to a Once which genetically-defined or Our define of to three X intent Phase recommended each cohort. distinct proceed refractory trial each established, a leukemia. are specific X for doses enroll cohorts, relapsed dose of is X expansion acute will the Phase recommended consists a
are, cohorts with Acute adults MLL-r MLL-r Myeloid Leukemia, and Lymphoid ALL, or with adults Leukemia, or three AML, AML. Acute adults with The NPMX mutant
patients intent specified for dosing these Our derived in Phase in guidelines II Phase cohorts to is two from have X.
measure the of as The initial of Phase further SNDX-XXXX benefit. the response therapeutic will rate safety of and X portion an characterize primary the provide will complete estimate
not from the fourth quarter of Phase are We the year Additional conference. medical updates I before of anticipate updates a the AUGMENT-XXX anticipated any further trial quarter. this the at in do fourth portion
of component into a our strategy. to eager are pediatric we as addition, advance molecule key population the this overall In
our We and more pediatric will future call. of say to details on have the timing the about approach
are know with We MLL-r we their a rearrangements represent oncology leukemias eager and to with pediatric to bring patients. need unmet SNDX-XXXX to work the community significant pediatric medical
trials Let combination CSF-X patients the from axatilamab, the presented monoclonal receptor. and multiple-ascending Results Slide our AACR me solid targeting alone with XX best-in-class virtual were now axatilamab week last formerly in tumors as therapy in known to during and exploring antibody turn SNDX-XXXX, the with potential meeting. dose durvalumab
dose and underscored at ability pro-inflammatory of pharmacodynamic and depletion and These biomarker sustained promote robust results modulation tolerability all axatilamab demonstrated to the circulating rapid of its monocytes tested. levels
cells and the of axatilamab for fibrosis hematopoietic transplantation, as a Chronic in initiated is a donor-derived rationale against graft-versus-host the stem disease cell CSF-XR development we and myriad wherein know, of manifestations and using the GVHD this immune the on complication disease. you initiation as testing monotherapy As frequent of inhibitor disease a trial to XX. Slide shown of contribute chronic
reducing anti-CSF-XR thereby We in CSF-X, an chronic disease. models, preclinical GVHD donor CSF-XR the preventing and result represents blocking chronic important with the clinical can depletion opportunity. of antibody graft-versus-host believe pathway macrophages, In
on initial a identify year, diagrammed we dose-escalation chronic XX. is treatment a the from trial to disease. axatilamab trial, of the The designed Phase maximum tolerated X recommended Last of and is Phase graft-versus-host dose for released Slide portion which the data X dose our X Phase
and released five the X include kilogram three a trial enrolled the dose. Phase data from the to first now milligram We modified at the per patients cohort the first have in cohorts one have
continue the more additional may will Phase or dose We as and open well. X formally recommended to Phase define one trial dose Phase the cohorts, X X
axatilamab and of Menin-MLL-r that led will quality to or programs. of Slide Finally, be assets. to we summarizes We the that in-licensing through XX able the acquisition pipeline expand believe our the differentiated to acquisition the continue transactions
evaluate We we to skill identify experience through points. to inflection bring compounds the valuable have the high-quality believe assets and necessary and development these clinical
to such transactions. remain among expect We partners preferred of
financial I'll now to over Rick Rick? results. our the to call review turn
